Skip to main content
Premium Trial:

Request an Annual Quote

Cincinnati Microarray Core Opts for NuGen s RNA Amplification Kit

NEW YORK, July 20 (GenomeWeb News) - NuGen Technologies said today that the microarray core facility at Cincinnati Children's Hospital Research Foundation has selected NuGen's Ovation Biotin RNA amplification system for all of its RNA target preparation protocols.

 

The core facility supports microarray analysis for researchers at Cincinnati Children's Hospital and the University of Cincinnati using the Affymetrix GeneChip platform.

 

Financial terms of the agreement were not provided.

 

NuGen signed a similar deal with the Genomics Core Laboratory at the J. David Gladstone Institute in June.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.